Artemis: Harnessing Knowledge Graphs for Next-Generation Drug Target Prioritization
Computational and Structural Biotechnology Journal · 01.03.2026 · 35 (1)
DOI: 10.34133/csbj.0130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Computational and Structural Biotechnology Journal, online erschienen am 26.06.2026. Verfasst von Vladimir Yu Kiselev und 1 weiteren Autor:innen. Beteiligte Einrichtung: Alethio Therapeutics, Abingdon, Oxfordshire OX14 3NB, UK. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Knowledge graphs (KGs) have become an important asset in biomedical research and drug discovery by enabling the structured integration of heterogeneous biological knowledge. When combined with machine learning (ML), KGs support the identification of novel drug–target relationships, but existing approaches are often KG-centric, relying primarily on graph structure and embeddings while overlooking disease-specific biological and clinical context. Moreover, many high-impact applications depend on proprietary KG infrastructures, limiting accessibility for the broader research community. Here, we introduce Artemis, a practical and generalizable ML framework for indication-aware target prioritization that integrates public biomedical KGs with clinical evidence from the ChEMBL database. Artemis derives graph-based representations of clinically validated drug targets from multiple publicly available KGs and trains supervised ML models using disease-relevant clinical labels derived from ChEMBL. This hybrid feature space is used to train supervised ML models across 7 disease indications, with performance assessed via cross-validation and guided parameter optimization. The framework is further evaluated on emerging breast cancer targets reported at the San Antonio Breast Cancer Symposium 2024, demonstrating its ability to prioritize novel candidates. Overall, this work demonstrates that publicly available KGs can be used for actionable, translational target discovery when coupled with clinical data. Artemis provides an accessible, scalable, and cost-efficient alternative to proprietary KG platforms, thereby offering a practical solution for researchers seeking to prioritize therapeutic targets in real-world drug discovery settings.
Autor:innen und Institutionen
- Alethio Therapeutics, Abingdon, Oxfordshire OX14 3NB, UK.
ORCID-Profile: Vladimir Yu Kiselev, Edward Ainscow
Zitieren
APA
Kiselev, V. Y., & Ainscow, E. (2026). Artemis: Harnessing Knowledge Graphs for Next-Generation Drug Target Prioritization. Computational and Structural Biotechnology Journal, 35(1). https://doi.org/10.34133/csbj.0130
Vancouver
Kiselev VY, Ainscow E. Artemis: Harnessing Knowledge Graphs for Next-Generation Drug Target Prioritization. Computational and Structural Biotechnology Journal. 2026;35(1). doi:10.34133/csbj.0130
BibTeX
@article{Kiselev2026,
author = {Kiselev, Vladimir Yu and Ainscow, Edward},
title = {Artemis: Harnessing Knowledge Graphs for Next-Generation Drug Target Prioritization},
journal = {Computational and Structural Biotechnology Journal},
year = {2026},
volume = {35},
number = {1},
doi = {10.34133/csbj.0130}
}
EUVIMED